Ciprofloxacin Hydrochloride Film-Coated Tablets:
Indicated for the treatment of urinary tract infections caused by sensitive bacteria, including acute pyelonephritis. Ciprofloxacin and ciprofloxacin rapid release tablets are not interchangeable.Simple urethral infection (acute cystitis) : caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, Staphylococcus saprophyticus A.Complex urinary tract infection: caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, Pseudomonas aeruginosa A.Acute simple pyelonephritis caused by e. coli.A: In studies to treat organ infections caused by this pathogen, fewer than 10 subjects were involved.The safety and efficacy of this product in the treatment of infections other than urinary tract infections have not been demonstrated.Bacterial cultures and susceptibility tests should be performed before drug treatment in order to isolate and identify the bacteria causing the infection and determine whether they are sensitive to ciprofloxacin.This product may be used until test results are available, and should not be used until results are available for ciprofloxacin treatment.Periodic bacterial cultures and drug sensitivity tests during treatment provide information not only on the efficacy of treatment but also on the likelihood of bacterial tolerance.
Reyoung Pharmaceutical Co., Ltd., established in 1966, is one of the leading manufacturer and distributor of pharmaceutical products in China. Reyoung Pharma is certificated by GMP, ISO9001, ISO14001, OHS18001. The trademark "REYOUNG" is famous trademark of China.
Reyoung Pharma has three main factories which covers an area of 1,000,000 square meters and owns total asset of more than 1.5 billion USD dollar. Reyoung Pharma has 30 workshops that can produce ten categories and more than 400 specifications of pharmaceutical products including tablets, capsules, granules, sterile active ingredients, small volume injection, powder for injection, lyophilized powder for injection, suppository, traditional Chinese medicine and aerosol. The annual production capacity can reach 2.5 billion vials of powder for injection, 300 million ampoules of liquid injection, 4 billion tablets, 6 billion capsules and 200 million bags granule of solid formulation, and 2000 tons API respectively.
As a professional pharmaceutical manufacturer, Reyoung Pharma is the first enterprise to manufacture powder for injection in Shandong province. The sales and marketing network for its products covers more than 70 countries all over the world.
Reyoung Pharma commenced international business and exported products in 1997. Reyoung Pharma, with an excellent sales & documentation team, owned over 20 years experience in the international transaction and registered products in different countries. Reyoung Pharma has passed the GMP inspection of Colombia, Peru, Congo, Ethiopia, Uganda, Nigeria, Ghana, Tanzania, Kenya, Cote d′Ivoire, Pakistan, Ukraine, Philippines, Cambodia, etc. Products have been exported to Asia, South America, Africa, CIS Countries, Middle East and Europe including Thailand, Philippines, Cambodia, Hong Kong, Vietnam, India, Pakistan, Colombia, Peru, Chile, Costa Rica, Venezuela, Congo, Ethiopia, Uganda, Nigeria, Tanzania, Kenya, Cameroon, Russia, Kazakhstan, Ukraine, Uzbekistan, Georgia, Yemen, Iraq, Germany, Denmark, and so on.
Look into the future, as entering into the market successively of the new products, the product structure of Reyoung Pharma will be upgraded, the producing levels and the market-controlling power will be enhanced further, and Reyoung Pharma will provide a wider platform for our old and new friends to go hand in hand and seek common development.
Audited Supplier 
){kind=link}
){kind=link}